Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 2165 entries
Sorted by: Best Match Show Resources per page
Words of wisdom. Re: Video endoscopic lymphadenectomy: a new minimally invasive procedure for radical management of inguinal nodes in patients with penile squamous cell carcinoma .

European urology

Carmignani G.
PMID: 18329979
Eur Urol. 2008 Feb;53(2):451-2. doi: 10.1016/j.eururo.2007.11.005.

No abstract available.

Cite
Carmignani G. Words of wisdom. Re: Video endoscopic lymphadenectomy: a new minimally invasive procedure for radical management of inguinal nodes in patients with penile squamous cell carcinoma . Eur Urol. 2008;53(2):451-2doi: 10.1016/j.eururo.2007.11.005.
Carmignani, G. (2008). Words of wisdom. Re: Video endoscopic lymphadenectomy: a new minimally invasive procedure for radical management of inguinal nodes in patients with penile squamous cell carcinoma . European urology, 53(2), 451-2. https://doi.org/10.1016/j.eururo.2007.11.005
Carmignani, Giorgi. "Words of wisdom. Re: Video endoscopic lymphadenectomy: a new minimally invasive procedure for radical management of inguinal nodes in patients with penile squamous cell carcinoma ." European urology vol. 53,2 (2008): 451-2. doi: https://doi.org/10.1016/j.eururo.2007.11.005
Carmignani G. Words of wisdom. Re: Video endoscopic lymphadenectomy: a new minimally invasive procedure for radical management of inguinal nodes in patients with penile squamous cell carcinoma . Eur Urol. 2008 Feb;53(2):451-2. doi: 10.1016/j.eururo.2007.11.005. PMID: 18329979.
Copy Download .nbib Format: NLM
Words of wisdom. Re: Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.

European urology

Kessler TM.
PMID: 18074438
Eur Urol. 2007 Dec;52(6):1793-4. doi: 10.1016/j.eururo.2007.09.024.

No abstract available.

Cite
Kessler TM. Words of wisdom. Re: Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. Eur Urol. 2007;52(6):1793-4doi: 10.1016/j.eururo.2007.09.024.
Kessler, T. M. (2007). Words of wisdom. Re: Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. European urology, 52(6), 1793-4. https://doi.org/10.1016/j.eururo.2007.09.024
Kessler, Thomas M. "Words of wisdom. Re: Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial." European urology vol. 52,6 (2007): 1793-4. doi: https://doi.org/10.1016/j.eururo.2007.09.024
Kessler TM. Words of wisdom. Re: Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. Eur Urol. 2007 Dec;52(6):1793-4. doi: 10.1016/j.eururo.2007.09.024. PMID: 18074438.
Copy Download .nbib Format: NLM
Re: Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis.

European urology

Messing EM.
PMID: 17415910
Eur Urol. 2007 Apr;51(4):1140. doi: 10.1016/j.eururo.2007.01.056.

No abstract available.

Cite
Messing EM. Re: Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Eur Urol. 2007;51(4):1140doi: 10.1016/j.eururo.2007.01.056.
Messing, E. M. (2007). Re: Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. European urology, 51(4), 1140. https://doi.org/10.1016/j.eururo.2007.01.056
Messing, Edward M. "Re: Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis." European urology vol. 51,4 (2007): 1140. doi: https://doi.org/10.1016/j.eururo.2007.01.056
Messing EM. Re: Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Eur Urol. 2007 Apr;51(4):1140. doi: 10.1016/j.eururo.2007.01.056. PMID: 17415910.
Copy Download .nbib Format: NLM
Re: Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading.

European urology

Bastian PJ.
PMID: 17415913
Eur Urol. 2007 Apr;51(4):1142-3. doi: 10.1016/j.eururo.2007.01.059.

No abstract available.

Cite
Bastian PJ. Re: Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. Eur Urol. 2007;51(4):1142-3doi: 10.1016/j.eururo.2007.01.059.
Bastian, P. J. (2007). Re: Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. European urology, 51(4), 1142-3. https://doi.org/10.1016/j.eururo.2007.01.059
Bastian, Patrick J. "Re: Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading." European urology vol. 51,4 (2007): 1142-3. doi: https://doi.org/10.1016/j.eururo.2007.01.059
Bastian PJ. Re: Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. Eur Urol. 2007 Apr;51(4):1142-3. doi: 10.1016/j.eururo.2007.01.059. PMID: 17415913.
Copy Download .nbib Format: NLM
Words of wisdom. Re: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.

European urology

Droller MJ.
PMID: 18061997
Eur Urol. 2006 Nov;50(5):1119-20. doi: 10.1016/j.eururo.2006.08.018.

No abstract available.

Cite
Droller MJ. Words of wisdom. Re: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. Eur Urol. 2006;50(5):1119-20doi: 10.1016/j.eururo.2006.08.018.
Droller, M. J. (2006). Words of wisdom. Re: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. European urology, 50(5), 1119-20. https://doi.org/10.1016/j.eururo.2006.08.018
Droller, Michael J. "Words of wisdom. Re: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay." European urology vol. 50,5 (2006): 1119-20. doi: https://doi.org/10.1016/j.eururo.2006.08.018
Droller MJ. Words of wisdom. Re: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. Eur Urol. 2006 Nov;50(5):1119-20. doi: 10.1016/j.eururo.2006.08.018. PMID: 18061997.
Copy Download .nbib Format: NLM
Words of wisdom. Re: Detection of occult nodal metastases in locally advanced node-negative prostate cancer.

European urology

Briganti A.
PMID: 18061998
Eur Urol. 2006 Nov;50(5):1120-1. doi: 10.1016/j.eururo.2006.08.019.

No abstract available.

Cite
Briganti A. Words of wisdom. Re: Detection of occult nodal metastases in locally advanced node-negative prostate cancer. Eur Urol. 2006;50(5):1120-1doi: 10.1016/j.eururo.2006.08.019.
Briganti, A. (2006). Words of wisdom. Re: Detection of occult nodal metastases in locally advanced node-negative prostate cancer. European urology, 50(5), 1120-1. https://doi.org/10.1016/j.eururo.2006.08.019
Briganti, Alberto. "Words of wisdom. Re: Detection of occult nodal metastases in locally advanced node-negative prostate cancer." European urology vol. 50,5 (2006): 1120-1. doi: https://doi.org/10.1016/j.eururo.2006.08.019
Briganti A. Words of wisdom. Re: Detection of occult nodal metastases in locally advanced node-negative prostate cancer. Eur Urol. 2006 Nov;50(5):1120-1. doi: 10.1016/j.eururo.2006.08.019. PMID: 18061998.
Copy Download .nbib Format: NLM
Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81.

European urology

Shariat SF, Karam JA, Karakiewicz PI.
PMID: 20050019
Eur Urol. 2009 Jan;55(1):250-2. doi: 10.1016/j.eururo.2008.09.037.

No abstract available.

Cite
Shariat SF, Karam JA, Karakiewicz PI. Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81. Eur Urol. 2009;55(1):250-2doi: 10.1016/j.eururo.2008.09.037.
Shariat, S. F., Karam, J. A., & Karakiewicz, P. I. (2009). Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81. European urology, 55(1), 250-2. https://doi.org/10.1016/j.eururo.2008.09.037
Shariat, Shahrokh F, et al. "Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81." European urology vol. 55,1 (2009): 250-2. doi: https://doi.org/10.1016/j.eururo.2008.09.037
Shariat SF, Karam JA, Karakiewicz PI. Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81. Eur Urol. 2009 Jan;55(1):250-2. doi: 10.1016/j.eururo.2008.09.037. PMID: 20050019.
Copy Download .nbib Format: NLM
Words of wisdom. Re: Comparative effectiveness of minimally invasive vs open radical prostatectomy.

European urology

van Leeuwen PJ.
PMID: 20135755
Eur Urol. 2010 Mar;57(3):539-40. doi: 10.1016/j.eururo.2009.12.013.

No abstract available.

Cite
van Leeuwen PJ. Words of wisdom. Re: Comparative effectiveness of minimally invasive vs open radical prostatectomy. Eur Urol. 2010;57(3):539-40doi: 10.1016/j.eururo.2009.12.013.
van Leeuwen, P. J. (2010). Words of wisdom. Re: Comparative effectiveness of minimally invasive vs open radical prostatectomy. European urology, 57(3), 539-40. https://doi.org/10.1016/j.eururo.2009.12.013
van Leeuwen, Pim J. "Words of wisdom. Re: Comparative effectiveness of minimally invasive vs open radical prostatectomy." European urology vol. 57,3 (2010): 539-40. doi: https://doi.org/10.1016/j.eururo.2009.12.013
van Leeuwen PJ. Words of wisdom. Re: Comparative effectiveness of minimally invasive vs open radical prostatectomy. Eur Urol. 2010 Mar;57(3):539-40. doi: 10.1016/j.eururo.2009.12.013. PMID: 20135755.
Copy Download .nbib Format: NLM
Words of wisdom. Re: hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study.

European urology

Morales A.
PMID: 19189434
Eur Urol. 2008 Dec;54(6):1437-8. doi: 10.1016/j.eururo.2008.08.042.

No abstract available.

Cite
Morales A. Words of wisdom. Re: hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. Eur Urol. 2008;54(6):1437-8doi: 10.1016/j.eururo.2008.08.042.
Morales, A. (2008). Words of wisdom. Re: hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. European urology, 54(6), 1437-8. https://doi.org/10.1016/j.eururo.2008.08.042
Morales, Alvaro. "Words of wisdom. Re: hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study." European urology vol. 54,6 (2008): 1437-8. doi: https://doi.org/10.1016/j.eururo.2008.08.042
Morales A. Words of wisdom. Re: hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. Eur Urol. 2008 Dec;54(6):1437-8. doi: 10.1016/j.eururo.2008.08.042. PMID: 19189434.
Copy Download .nbib Format: NLM
Re: Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy.

European urology

Kliment J.
PMID: 19691136
Eur Urol. 2009 Aug;56(2):397. doi: 10.1016/j.eururo.2009.05.034.

No abstract available.

Cite
Kliment J. Re: Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Eur Urol. 2009;56(2):397doi: 10.1016/j.eururo.2009.05.034.
Kliment, J. (2009). Re: Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. European urology, 56(2), 397. https://doi.org/10.1016/j.eururo.2009.05.034
Kliment, Jan. "Re: Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy." European urology vol. 56,2 (2009): 397. doi: https://doi.org/10.1016/j.eururo.2009.05.034
Kliment J. Re: Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Eur Urol. 2009 Aug;56(2):397. doi: 10.1016/j.eururo.2009.05.034. PMID: 19691136.
Copy Download .nbib Format: NLM
Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.

European urology

Shuch B, Belldegrun A.
PMID: 18485320
Eur Urol. 2008 May;53(5):1085-6. doi: 10.1016/j.eururo.2008.02.010.

No abstract available.

Cite
Shuch B, Belldegrun A. Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Eur Urol. 2008;53(5):1085-6doi: 10.1016/j.eururo.2008.02.010.
Shuch, B., & Belldegrun, A. (2008). Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. European urology, 53(5), 1085-6. https://doi.org/10.1016/j.eururo.2008.02.010
Shuch, Brian, and Belldegrun, Arie. "Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma." European urology vol. 53,5 (2008): 1085-6. doi: https://doi.org/10.1016/j.eururo.2008.02.010
Shuch B, Belldegrun A. Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Eur Urol. 2008 May;53(5):1085-6. doi: 10.1016/j.eururo.2008.02.010. PMID: 18485320.
Copy Download .nbib Format: NLM
Words of wisdom. Re: EPCA-2: a highly specific serum marker for prostate cancer.

European urology

Katz MD, Kibel AS.
PMID: 18240414
Eur Urol. 2008 Jan;53(1):210. doi: 10.1016/j.eururo.2007.10.022.

No abstract available.

Cite
Katz MD, Kibel AS. Words of wisdom. Re: EPCA-2: a highly specific serum marker for prostate cancer. Eur Urol. 2008;53(1):210doi: 10.1016/j.eururo.2007.10.022.
Katz, M. D., & Kibel, A. S. (2008). Words of wisdom. Re: EPCA-2: a highly specific serum marker for prostate cancer. European urology, 53(1), 210. https://doi.org/10.1016/j.eururo.2007.10.022
Katz, Matthew D, and Kibel, Adam S. "Words of wisdom. Re: EPCA-2: a highly specific serum marker for prostate cancer." European urology vol. 53,1 (2008): 210. doi: https://doi.org/10.1016/j.eururo.2007.10.022
Katz MD, Kibel AS. Words of wisdom. Re: EPCA-2: a highly specific serum marker for prostate cancer. Eur Urol. 2008 Jan;53(1):210. doi: 10.1016/j.eururo.2007.10.022. PMID: 18240414.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 2165 entries